We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$17.2M
Cap. Flow
+$30.8M
Cap. Flow %
1.22%
Top 10 Hldgs %
72.66%
Holding
32
New
3
Increased
6
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$25.2M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$20.6M
3
MGNX icon
MacroGenics
MGNX
+$11.7M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$10.5M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$10M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$33.5M
2
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$14.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$10.1M
4
TSRO
TESARO, Inc.
TSRO
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 85.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$356M 14.05%
3,609,298
– –
INCY icon
2
Incyte
INCY
$24.4B
$307M 12.12%
3,840,406
– –
GILD icon
3
Gilead Sciences
GILD
$165B
$231M 9.14%
2,774,596
– –
IONS icon
4
Ionis Pharmaceuticals
IONS
$9.4B
$165M 6.53%
7,104,838
+325,000
+5% +$10.5M
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$160M 6.33%
4,360,399
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.6B
$142M 5.6%
3,121,552
– –
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$138M 5.44%
1,179,428
+145,000
+14% +$20.6M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$126B
$122M 4.81%
1,415,445
+50,000
+4% +$4.32M
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$120M 4.74%
1,991,112
-590,000
-23% -$33.5M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.93B
$99M 3.91%
2,363,321
+203,400
+9% +$10M
TSRO
11
DELISTED
TESARO, Inc.
TSRO
$97M 3.83%
1,154,582
-75,000
-6% -$3.34M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$80.8B
$71.6M 2.83%
205,000
– –
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$29.3B
$66.1M 2.61%
1,191,338
– –
HALO icon
14
Halozyme
HALO
$12.2B
$63.7M 2.51%
7,379,832
– –
NVAX icon
15
Novavax
NVAX
$1.31B
$60.6M 2.39%
416,500
– –
JUNO
16
DELISTED
Juno Therapeutics, Inc.
JUNO
$50.2M 1.98%
1,305,000
– –
ALDR
17
DELISTED
Alder Biopharmaceuticals
ALDR
$42.1M 1.66%
1,685,150
+175,000
+12% +$4.73M
KITE
18
DELISTED
Kite Pharma, Inc.
KITE
$37.5M 1.48%
750,000
– –
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$36.5M 1.44%
255,719
– –
CEMP
20
DELISTED
Cempra, Inc.
CEMP
$33.7M 1.33%
2,041,900
– –
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$27.2M 1.07%
+700,000
New +$25.2M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$25.6M 1.01%
850,639
+16,976
+2% +$566K
MGNX icon
23
MacroGenics
MGNX
$257M
$14M 0.55%
+520,000
New +$11.7M
PBYI icon
24
Puma Biotechnology
PBYI
$454M
$12.9M 0.51%
431,991
– –
PRTA icon
25
Prothena Corp
PRTA
$450M
$12.2M 0.48%
350,000
– –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2016 Portfolio in Review

As of Q2 2016, BB Biotech held 32 positions worth $2.53B, up 0.68% from $2.52B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BB Biotech's Q2 2016 filing shows 3 new, 6 increased, 2 reduced and 2 closed positions. Its largest new stake was Intra-Cellular Therapies Inc.: 700,000 shares worth $27.2M. The largest sale was MEDIVATION, INC., an estimated $33.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier.

  • BB Biotech's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 700,000 shares worth $27.2M.
  • BB Biotech added most to Alexion Pharmaceuticals in Q2 2016, an estimated $20.6M increase.
  • BB Biotech's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $33.5M.
  • BB Biotech fully exited Infinity Pharmaceuticals, Inc. in Q2 2016, selling an estimated $14.2M.
  • BB Biotech's ten largest holdings make up 73% of its $2.53B portfolio in Q2 2016.
  • BB Biotech opened 3 new positions and closed 2 in Q2 2016.
  • BB Biotech's portfolio value rose 0.68% quarter-over-quarter to $2.53B.

Based on BB Biotech's 13F filing for Q2 2016, filed 12 Aug 2016.